Various approaches to the synthesis of all four stereoisomers of 2-(1H-imidazol-4-yl)cyclopropylamine (cyclopropylhistamine) are described. The rapid and convenient synthesis and resolution of trans-cyclopropylhistamine is reported. The absolute configuration of its enantiomers was determined by single-crystal X-ray crystallographic analysis. The distinct transcyclopropylhistamine enantiomers were tested for their activity and affinity on the histamine H 3 receptor. (1S,2S)-Cyclopropylhistamine (VUF 5297) acts as an agonist both on the rat cortex (pD 2 ) 7.1; R ) 0.75) and on guinea pig jejunum (pD 2 ) 6.6; R ) 0.75). Its enantiomer, (1R,2R)-cyclopropylhistamine (VUF 5296), is about 1 order of magnitude less active. Both enantiomers show weak activity on H 1 and H 2 receptors. All synthetic attempts to cis-cyclopropylhistamine were unsuccessful. Nevertheless, the results of this study provide an ideal template for molecular modeling studies of histamine H 3 receptor ligands.
Introduction
Next to its role as mediator in (patho)physiological processes, histamine can be regarded as a neurotransmitter. 1 The different pharmacological actions of histamine 2 are mediated via the activation of distinct histamine receptor subtypes. In addition to two postsynaptic receptor subtypes, H 1 and H 2 , a presynaptic H 3 receptor has been identified. The histamine H 3 receptor is responsible for controlling neuronal synthesis of histamine and in addition regulates the release of the neurotransmitter into the synaptical cleft. 3 Furthermore, the receptor has been shown to modulate the release of other neurotransmitters, e.g., serotonin, 4, 5 acetylcholine, 6 dopamine, 7 and noradrenaline, 8 in both the central nervous system (CNS) and the peripheral nervous system. Therefore the H 3 receptor can be considered a potential target for the development of new therapeutic agents, e.g., to treat neurologic disorders. 9 To determine the precise functional roles of the H 3 receptor, it is necessary to develop potent and selective H 3 ligands. Design of such compounds can be facilitated by molecular modeling. Furthermore, such studies can help to better understand the molecular mechanisms involved in receptor stimulation. Therefore, the struc-tural features that are responsible for affinity and intrinsic activity of a ligand need to be resolved.
The development of rigid histamine analogues will contribute to the determination of the H 3 receptor pharmacophore, as the conformations of these compounds only allow restricted spatial orientation of the pharmacophoric elements of H 3 receptor agonists, i.e., the orientation of the imidazole ring with respect to the basic nitrogen in the side chain of the ligands. A small and rigid compound such as 2-(1H-imidazol-4-yl)cyclopropylamine (cyclopropylhistamine) (1) would be an ideal template for the development of a pharmacophore model, using molecular modeling techniques. Some preliminary pharmacological data for this compound have been reported in a patent application by Arrang et al. 10 Unfortunately, the stereochemical identity of the material tested was not reported. Hence, we speculated that the results reported by Arrang and co-workers could be based on experiments with racemic mixtures of both the trans-and cis-diastereoisomers (denoted here as 1a,b and 1c,d, respectively; Figure 1 ). As the H 3 receptor has proved to be highly stereoselective, 11, 12 it is reasonable to assume that each of the stereoisomers will have a different activity. For molecular modeling studies, the potencies of each of the distinct isomers has to be determined. Therefore, we decided to attempt to synthesize the four stereoisomers of cyclopropylhistamine and to study their respective H 3 pharmacology.
Chemistry
In the aforementioned patent application by Arrang et al. 10 cyclopropylhistamine (1) was obtained via a route developed by Burger and co-workers. 13 In this route, cyclopropylhistamine (1) was synthesized starting from urocanic acid (2) , via the cyclopropanation of sec-butyl trans-3-(1-trityl-1H-imidazol-4-yl)acrylate ((E)-3) with dimethyloxosulfonium methylide followed by a Curtius rearrangement of the carboxylate group (Scheme 1). In our hands, the key step in this synthesis scheme, the cyclopropanation step, yielded a racemic mixture of trans-cyclopropane 4a,b in a moderate yield (41%).
No cyclopropane product with the cis-configuration was detected in the reaction mixture. Efforts to obtain cis-cyclopropylhistamine (1c,d) via cyclopropanation of the isomeric sec-butyl cis-3-(1-trityl-1H-imidazol-4-yl)-acrylate 14 ((Z)-3) as starting material also failed. Only trans-cyclopropanane product 4a,b was obtained. Variation of the reaction conditions and use of other protective groups for the imidazole moiety or the carboxylate group could neither improve the yield nor improve the stereochemical outcome of the reaction. The addition of sulfonium ylide to the double bond proceeds via a nonconcerted reaction mechanism, and theoretically the formation of a mixture of all four cyclopropane stereoisomers is possible. However, we have to conclude that the addition to urocanic acid derivatives exclusively leads to the thermodynamically most stable product having the trans-cyclopropane configuration, regardless of the configuration of the unsaturated bond in the starting material.
Subsequently, we investigated other methods to obtain this compound in a stereoselective manner. Cyclopropanation of the urocanate (E)-5 by the stereospecific addition of diazomethane, using palladium(II) acetate as a catalyst, gave the trans-cyclopropane 6a,b in a moderate yield (Scheme 2). However, it must be noted that higher temperatures, larger amounts of catalyst, and repeated applications of the reaction conditions were required compared to the reported cyclopropanations of analogous non-imidazole R, -unsaturated carboxylic esters. [15] [16] [17] Alkaline hydrolysis of the ester 6a,b and subsequent Curtius rearrangement yielded the racemic trans-cyclopropylhistamine (1a,b). Having obtained only a limited amount of trans-cyclopropylhistamine (1a,b) we were unable to separate the enantiomers.
For the synthesis of the cis-isomers of cyclopropylhistamine (1c,d), the intermediate cis-urocanate (Z)-5 was prepared by a new synthetic pathway (Scheme 3). 4-Iodo-1H-imidazole (7) protected with an N,N-dimethylsulfamoyl group was coupled to trimethylsilylacetylene in a palladium-catalyzed reaction. 17, 18 Removal of the trimethylsilyl group by treatment with KOH gave the acetylenic derivative 10 which was treated with ethylmagnesium bromide and dimethyl carbonate to provide alkyne ester 11. Subsequent hydrogenation over Lindlar catalyst 19 yielded the cis-urocanate (Z)-5. However, palladium-catalyzed cyclopropanation of this compound failed. All attempts to perform this reaction under the same, or even more drastic, conditions compared to the trans-urocanate (E)-5 did not give the desired product; only starting material was recovered.
Other metal-catalyzed cyclopropanation procedures (e.g., Simmons-Smith reactions) on trans-urocanic acid derivatives such as (E)-5 gave even lower yields of transcyclopropanated product. When using cis-urocanic acid derivatives such as (Z)-5, these methods failed completely to give cyclopropanated product. We suggest that the transition-metal-catalyzed cyclopropanations are seriously hampered because of chelation of the catalyst by the imidazole moiety.
We had to conclude that the strategy to synthesize all isomers of cyclopropylhistamine (1) by cyclopropanation of imidazole-containing precursors suffered from serious drawbacks. The trans-isomers 1a,b were obtained in a moderate yield, and the limited availability of the racemic compound hampered efforts to separate the enantiomers. Furthermore, all attempts to synthesize the cis-isomers 1c,d failed.
Therefore, we changed our strategy and developed a new synthesis route, constructing the imidazole ring on an appropriate cyclopropyl precursor (Scheme 4). Commercially available racemic ethyl trans-2-formyl-1-cyclopropanecarboxylate (12a,b) was allowed to react with (p-tolylsulfonyl)methyl isocyanide (TosMIC) in a [3+2] anionic cycloaddition. 20 The labile 4-tosyloxazoline 13a,b which precipitated from the reaction mixture was filtered and immediately treated with a saturated solution of ammonia in ethanol at 120°C. Both reaction steps proceed rapidly and in high yields.
The imidazole nucleus in 14a,b was protected with a dimethylsulfamoyl group, and the ester 15a,b was hydrolyzed under basic conditions. Subsequent Curtius rearrangement gave the isocyanate 16a,b which was converted directly into the diastereomeric carbamates 17 and 18 using the enantiopure alcohol (R)-(+)-1-(2-naphthyl)ethanol. The diastereomers were easily separated by flash column chromatography. The diastereomeric purity of the isolated stereoisomers was verified by HPLC analysis. The absolute configuration of 18 was determined by single-crystal X-ray analysis ( Figure 2 ) (for details, see the Experimental Section).
Hydrolysis of the distinct diastereoisomers with hydrobromic acid gave the enantiopure trans-cyclopropylhistamines (1a,b).
In an attempt to prepare cis-cyclopropylhistamine (1c,d) via an analogous route, racemic ethyl cis-2-formylcyclopropylcarboxylate 21 was reacted with TosMIC. This resulted in the precipitation of a highly unstable compound that could not be characterized. Immediate treatment of this material with ammonia in ethanol resulted in the formation of tars from which no cyclopropylimidazoles could be isolated or identified.
Pharmacological Data
The agonistic activities of the compounds 1a,b on the histamine H 3 receptor were determined on an in vitro test system based on the electrically evoked contractile response of isolated guinea pig jejunum segments. 22 The receptor activities were also measured via the release of [ 3 H]noradrenaline from electrically stimulated rat cerebral cortex slices. 23 Binding affinities were determined using an H 3 receptor binding assay on rat cortex (for details, see the Experimental Section). The compounds were additionally tested for H 2 agonism on the spontaneously beating guinea pig right atrium 24 and for H 1 agonism on guinea pig ileum segments (Table  1) Table 1 . Agonistic Activities, Intrinsic Activity (R), and Binding Affinity of the Enantiopure trans-Cyclopropylhistamines
a Functional H3 receptor assay on rat cortex. b Functional H3 receptor assay on guinea pig jejunum. c H3 receptor binding assay on rat cortex. d Functional H2 receptor assay on guinea pig atrium. e Functional H1 receptor assay on guinea pig jejunum.
Discussion
The histamine H 3 receptor affinity of cyclopropylhistamine (1) has been reported in a patent application by Arrang et al. 10 We assume that the material tested by Arrang and co-workers was a racemic mixture of transcyclopropylhistamine (1a,b). In our efforts to synthesize all four stereoisomers, we have developed a new route for the large-scale synthesis and resolution of transcyclopropylhistamine (1a,b). However, all synthetic attempts to cis-cyclopropylhistamine (1c,d) were unsuccessful.
Pharmacological evaluation of the enantiopure products 1a,b confirmed once more the stereoselectivity of the H 3 receptor. We established (1S,2S)-2-(1H-imidazol-4-yl)cyclopropylamine (1b) (VUF 5297) as the eutomer, having moderate H 3 activity. Its enantiomer VUF 5296 is about 10 times less potent. Both stereoisomers show partial agonistic activity. Minor differences in potencies between the two functional assays were found. Therefore, the suggested H 3 receptor heterogeneity 2 is not manifested by compounds 1a,b.
During the preparation of this manuscript, Khan et al. 26 reported the synthesis of trans-cyclopropylhistamine (1a,b) via a diastereomeric synthesis route analogous to the route developed by Burger et al. 13 Surprisingly, they reported (1R,2R)-2-(1H-imidazol-4-yl)cyclopropylamine (1a) to be the most active enantiomer. Unfortunately, no analytical characterization of the ligands was reported by Khan and co-workers; we were therefore unable to compare the optical rotation of the cyclopropylhistamines prepared in the different laboratories. It should be noted that a modeling study by Sippl et al. 27 suggested that (1S,2S)-cyclopropylhistamine (1b) provided the best sterical agreement with the derived H 3 receptor pharmacophore model. Our present study supports these theoretical findings.
The rigid cyclopropylhistamine derivatives show only a moderate to low H 1 and H 2 receptor activity. The histamine H 1 receptor has a slight preference for the (1S,2S)-enantiomer 1b.
Conclusion
A rapid and convenient synthesis and resolution of trans-2-(1H-imidazol-4-yl)cyclopropylamine (trans-cyclopropylhistamine) is described. (1S,2S)-2-(1H-imidazol-4-yl)cyclopropylamine (VUF 5297) (1b) is a rigid H 3 receptor agonist about 10 times more active as its enantiomer. These results have enabled us to construct an unambiguous pharmacophore model for the histamine H 3 receptor, explaining agonistic and antagonistic activity of histamine H 3 ligands, as will be published elsewhere. 28 
Experimental Section
Chemistry. 1 H and 13 C NMR spectra were recorded on a Bruker AC-200 spectrometer with tetramethylsilane as an internal standard. Mass spectra were recorded on a Finnigan MAT-90 spectrometer. Melting points were determined on a Mettler FP-5 + FP-52 apparatus and are uncorrected. GLC analysis was performed on a Shimadzu GC-14A instrument equipped with an FID detector and an HP1 column (50 m × 0.31 mm). Elemental analyses was performed by Micro Kemi AB, Uppsala, Sweden. Solvents were purified and dried by standard procedures before use. 3-(1H-Imidazol-4-yl) acrylate. Urocanic acid (25.0 g, 0.18 mol) was added to refluxing methanol (150 mL), and HCl gas was bubbled through the mixture, according to literature procedures. 29 After refluxing for 5 h, the clear solution was cooled to 5°C and white needlelike crystals appeared (32.20 g, 94.4%). Mp: 233.5-234.5°C.
Methyl (E)-
Methyl ( The light-yellow solution became dark-brown, and N2 evolution was observed. The reaction mixture was stirred overnight. After the addition of a few drops acetic acid, the reaction mixture was washed with 5% NaHCO3 solution (250 mL). The organic layer was dried over Na2SO4, filtered over a short silica column, and concentrated in vacuo. The remaining light-yellow oil consisted of 49% product 6a,b and 51% starting material (GC and 1 H NMR). The residue was dissolved in dichloromethane (1 L), and the procedure was repeated, employing the same amounts of reagents. This time the residual oil consisted of 82% cyclopropane product and 18% starting material. 1 The crude product was dissolved in a mixture of methanol (100 mL) and tetrahydrofuran (100 mL). A portion of 1 M KOH solution (100 mL) was added, and after 0.5 h of stirring at room temperature, the mixture was washed with dichloromethane (3 × 200 mL). The aqueous layer was treated with 1 M HCl solution until the mixture had a pH of 2. The product was extracted with dichloromethane (3 × 200 mL), and after drying over Na 2SO4, filtration, and evaporation of the dichloromethane, a light-brown solid (3.91 g) remained. After several triturations with dry acetone, a white powder (2.92 g, 58.4%) was collected. Mp: 166.0°C. 1 
trans-2-(1H-Imidazol-4-yl)cyclopropylamine (1a,b). Racemic trans-2-(1-(N,N-dimethylsulfamoyl)-1H-imidazol-4-yl)-
cyclopropanecarboxylic acid (2.22 g, 8.6 mmol) was dissolved in dry acetone (65 mL) and triethylamine (1.6 mL, 11.5 mmol) under N2 atmosphere. The reaction mixture was cooled to 0°C
, and ethyl chloroformate (1.6 mL, 16.7 mmol) was added dropwise (a white precipitate formed). After 2 h, a solution of sodium azide (0.85 g, 13.1 mmol in 15 mL of H2O) was added slowly, and the mixture was stirred for another hour. After addition of H2O (65 mL), the solution was concentrated in vacuo until the water layer remained. The water layer was extracted with toluene (3 × 65 mL), and the combined toluene layers were dried over Na2SO4, filtered, and refluxed for 2 h (N2 evolution was observed). The residue after evaporation of toluene was refluxed in tert-butyl alcohol (50 mL) for 12 h (disappearance of the isocyanate peak in IR spectrum). After evaporation of the alcohol a dark residue remained. This residue was dissolved in ethyl acetate and filtered over a short silica column. A white solid (2.10 g) remained after evaporation of the ethyl acetate. This was refluxed for 12 h in 1 M HCl (100 mL). After concentration in vacuo, the residue was refluxed in absolute ethanol (60 mL) for 0.5 h, concentrated, and subsequently washed with acetone. A beige solid (1.06 g, 63%) remained, which was recrystallized from 2-propanol/ ether. Mp: 187.0-187.5°C. 1 The residue 9 was dissolved in methanol (150 mL) and tetrahydrofuran (150 mL). A solution of 2 M potassium hydroxide (150 mL) was added, and the mixture was poured in a saturated NH 4Cl solution (150 mL). After extraction of the product with dichloromethane (1 × 300 mL, 2 × 100 mL), drying over Na2SO4, filtration, and evaporation of the solvent, a brown oil (12.3 g) remained. The oil was purified by column chromatography using ethyl acetate as eluent (Rf ) 0.7). A light-beige solid (1-(N,N-dimethylsulfamoyl)-4-ethynyl-1H-imidazole) (7.82 g, 59%) was isolated. 1 H NMR (CDCl3) 10: δ 2.88 (s, 6H), 3.13 (s, 3H), 7.42 (s, 1H), 7.83 (s, 1H).
This beige solid 10 (5.0 g, 25 mmol) was dissolved in dichloromethane (50 mL) and added dropwise to a Grignard mixture, prepared from magnesium (0.8 g, 33 mmol) and ethyl bromide (2.5 mL, 33 mmol) in tetrahydrofuran (5 mL). After 1 h the mixture was poured in dimethyl carbonate (100 mL) and stirred overnight. The solution was poured in H 2O (250 mL) and extracted with dichloromethane (3 × 200 mL). After evaporation of the solvents, a brown oil (5.53 g) remained, which was purified on a silica gel column with ethyl acetate as eluent (R f ) 0.8). After two recrystallizations from 2-propanol, white crystals (2.98 g, 46%) were collected. Mp: 126.0-127.0°C. 1 
Methyl (Z)-3-(1-(N,N-Dimethylsulfamoyl)-1H-imidazol-4-yl)acrylate (5).
Compound 11 (2.6 g, 10.1 mmol) was dissolved in acetone (75 mL). Lindlar catalyst (120 mg) and quinoline (300 mg) were added, and the reaction mixture was stirred under hydrogen atmosphere (1 atm). After hydrogen consumption had ceased, additional Lindlar catalyst was added (repeated twice; a total of 280 mg of catalyst extra was added). After 8 h and 300 mL of hydrogen gas consumption, the reaction mixture was filtered and concentrated in vacuo. The residue consisted of 92% cis-and 8% trans-isomer, according to GC. This was purified on a silica gel column with ethyl acetate as eluent (R f ) 0.5) and recrystallization from nhexane. White crystals (1.8 g, 69%) were isolated. Mp: 74.0°C (13a,b) . To a stirred suspension of tosylmethyl isocyanide (6.8 g, 34.6 mmol) and ethyl trans-2-formyl-1-cyclopropanecarboxylate (12a,b) (5.0 g, 35.2 mmol) in absolute ethanol (250 mL) at 0°C was added sodium cyanide (45 mg). For a moment the reaction mixture became clear followed by precipitation of the product. Ten minutes after the addition of sodium cyanide, the suspension was filtered and product was washed with ether/hexane (20 mL, 1/1, v/v) and dried in vacuo. The product was isolated as a white hygroscopic solid (9.9 g, 85%). Mp: 107.0°C. 1 H NMR (CDCl3): δ 0.96-1.06 (m, 1H), 1.25 (t, J ) 7.14 Hz, 3H), 1.55- 1.77 (m, 2H), 1.79-1.89 (m, 1H), 2.55 (s, 3H), 4.12 (q, J ) ylate (14a,b) . In a stainless steal bomb, a solution of oxazoline 13a,b (9.0 g, 26.7 mmol) and saturated solution of ammonia in absolute ethanol (120 mL) was heated at 120°C for 25 h. The pressure increased to 12 atm. After cooling, the solvent was removed under reduced pressure. The dark, oily residue was dissolved in ethyl acetate/dichloromethane (150 mL, 4/1, v/v) and washed with saturated aqueous sodium chloride (5 × 50 mL). The organic layer was dried over sodium sulfate, filtered, and concentrated in vacuo to give the product as an oil (3.56 g, 74%). 1 H NMR (CDCl3): δ 1.18 (t, J ) 7.14 Hz, 3H), 1.28-1.38 (m, 1H), 1.39-1.48 (m, 1H), 1.82-1.93 (m, 1H), 2.37-2.48 (m, 1H), 4.06 (q, J ) 7.14 Hz, 2H), 6.77 (s, 1H), 7.45 (s, 1H). (15a,b) . To a solution of 14a,b (3.00 g, 16.9 mmol) and triethylamine (5.0 mL, 36.1 mmol) in dichloromethane (70 mL) was added N,N-dimethylsulfamoyl chloride (3.1 mL, 28.9 mmol). Subsequently, the reaction mixture was refluxed for 22 h. Concentration under reduced pressure followed by flash column chromatography (ethyl acetate/hexane, 5/3, v/v, R f ) 0.5) gave the product as a yellow oil (4.13 g, 85%). 1 H NMR (CDCl3): δ 1.26 (t, J ) 6.67 Hz, 3H), 1.37-1.58 (m, 2H), 1.98-2.10 (m, 1H), 2.36-2.48 (m, 1H), 2.87 (s, 6H), 4.14 (q, J ) 6.67 Hz, 2H), 7.04 (s, 1H), 7.72 (s, 1H).
Ethyl trans-2-(1-(N,N-Dimethylsulfamoyl)-1H-imidazol-4-yl)cyclopropanecarboxylate
trans-2-(1-(N,N-Dimethylsulfamoyl)-1H-imidazol-4-yl)-cyclopropanecarboxylic Acid. Compound 15a,b (2.5 g, 8.69 mmol) was dissolved in a mixture of methanol (100 mL) and THF (100 mL). At room temperature, 1 M KOH solution (100 mL) was added, and after 0.5 h stirring, the mixture was washed with dichloromethane (3 × 100 mL). The water layer was acidified with 1 M HCl until a pH of 2 and extracted with dichloromethane (3 × 100 mL). The organic layer was dried over sodium sulfate, filtered, and concentrated in vacuo to give a white powder (2.25 g, 75%). Mp: 166.0°C. 1 (25 mL) was added slowly to the formed suspension and stirred for an additional hour. After addition of water (100 mL), the solution was extracted with toluene (3 × 100 mL). The organic layer was dried over sodium sulfate. After filtration, the solution was refluxed for 2 h (N 2 evolution was observed). Subsequently, (R)-(+)-1-(2-naphthyl)ethanol (3.26 g, 18.9 mmol) was added. The mixture was refluxed for 13 h. After evaporation of the solvent, the diastereomeric carbamates were isolated using a short silica gel column (ethyl acetate, Rf ) 0.6) to give a white powder (6.41 g, 87%). The ratio of diastereoisomers was determined using HPLC analysis as 50:50 (Chrompack CPtm SpherSi, eluent ethyl acetate/ hexane, 60/40, v/v, at 1 mL/min; P ) 20 bar) ( X-ray crystal data for 18: F(000) ) 452, room temperature; final R ) 0.096 for 876 observed reflections.
A crystal with approximate dimensions of 0.03 × 0.05 × 0.60 mm was used for data collection on an Enraf-Nonius CAD-4 diffractometer with graphite-monochromated Cu KR radiation and ω-2θ scan. A total of 2403 unique reflections were measured within the range -16 e h e 15, 0 e k < 6, 0 e l e 19. Of these, 876 were above the significance level of 2.5σ(I). The range of (sin θ)/λ was 0.034-0.609 Å -1 (3.0 < θ < 69.9°). Two reference reflections (203, 212) were measured hourly and showed no decrease during the 57-h collecting time. In addition, 611 "Friedel" reflections were measured, which were used in the determination of the absolute configuration. Unitcell parameters were refined by least-squares fitting procedure using 23 reflections with 68 < 2θ < 78°. Corrections for Lorentz and polarization effects were applied. The structure was solved by the PATTY option of the DIRDIF94 program system. 30 The hydrogen atoms restraining the latter in such way that the distance to their carrier remained constant at approximately Pharmacology. The compounds were tested for their activity on the histamine receptors in different assays (vide supra). These assays were previously described in detail. [22] [23] [24] [25] The histamine H3 receptor affinity was determined in rat cortical membranes with [ 3 H]-N R -methylhistamine (81.9 Ci/ mmol; NEN Life Science Products, Brussels, Belgium) according to the method of West et al. 36 with modifications. Briefly animals were killed by decapitation, and the cerebral cortex was rapidly removed. Rat cortices were homogenized in 15 volumes (wt/vol) of ice-cold Tris/HCl buffer (50 mM Tris/HCl, 5 mM MgCl 2, 145 mM NaCl, pH 7.4 at 4°C) using an UltraTurrax homogenizer (8 s) and a glass-Teflon homogenizer (four strokes up and down) subsequently. All subsequent steps were carried out at 0-4°C. The homogenate was centrifuged at 800g for 10 min. The pellets were discarded, and the supernatant was centrifuged for 20 min at 40000g. The resulting pellet was resuspended, and the last centrifugation step was repeated. The pellet was resuspended in 1.5 volumes (wt/vol) of Tris/HCl buffer to give a final concentration of ∼300 µg/100 µL and stored in aliquots at -80°C. Protein concentration was determined using Biorad protein assay (Bio-Rad Laboratories GmbH, Munich, Germany). Competition binding experiments were carried out in polypropylene tubes in a total volume of 400 µL of 50 mM Na + phosphate buffer, pH 7.4 at 37°C, containing 30 µg of protein, 1 nM [ 3 H]-N R -methylhistamine, and 0.1-10 000 nM compound to be tested. Samples were incubated for 40 min at 25°C. The incubation was started by the addition of 100 µL of membranes (30 µg) and terminated by rapid filtration through poly(ethylenimine) (0.3 wt %/vol) pretreated Whatman GF/C filters using a Brandel filtration apparatus. The filters were washed twice with 3 mL of icecold Tris/HCl buffer (50 mM Tris/HCl, 5 mM MgCl 2, 145 mM NaCl, pH 7.4 at 4°C). The radioactivity retained on the filters was measured using liquid scintillation counting. Competition isotherms were analyzed with the GraphPad Prism software (GraphPad, Intuitive Software for Science, San Diego, CA). K i values were determined with the equation Ki ) IC50/(1 + ([ligand]/Kd)).
